A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-06-01
AEs
4
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 75); relationship: not assessed
moderate
assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-27 (study day 110); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-10 (study day 336); relationship: N
severe
assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-08-30 (study day 448); relationship: not assessed
Data queries
No data queries.